Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ClouDr GroupFRA:H3L 48 Shareholder Yield % is 20.57% as of Dec. 2025. GuruFocus rates FRA:H3L with a GF Score™ of 48/100 and a GF Value™ of €0.08. The stock has 9 warning signs investors should review. Among 114 Medical Distribution companies, ClouDr Group ranks better than 87.72% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, ClouDr Group's Shareholder Yield % was 20.57%.
ClouDr Group (FRA:H3L) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
ClouDr Group Shareholder Yield % Related Terms
ClouDr Group Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for ClouDr Group's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:H3L vs MCK, COR, CAH: Shareholder Yield % Comparison
For the Medical Distribution subindustry, ClouDr Group's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ClouDr Group Shareholder Yield % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, ClouDr Group's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where ClouDr Group's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
ClouDr Group (FRA:H3L) has a Shareholder Yield % of 20.57% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on ClouDr Group and its competitors. According to the industry distribution chart, ClouDr Group ranks #14 out of 114 companies in the Medical Distribution industry, placing it in the top 12.3%.
Is ClouDr Group's Shareholder Yield % too high?
ClouDr Group's current Shareholder Yield % is 20.57%. The Medical Distribution industry median Shareholder Yield % is 2.17. ClouDr Group's value of 20.57% is 847.9% above this industry median. Based on the distribution chart, ClouDr Group ranks #14 out of 114 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, ClouDr Group has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does ClouDr Group's Shareholder Yield % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, ClouDr Group ranks #14 out of 114 companies for Shareholder Yield %. This places ClouDr Group in the top 12% of its industry — outperforming the majority of peers. The industry median Shareholder Yield % is 2.17. ClouDr Group's value of 20.57% is 847.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Distribution company?
The median Shareholder Yield % among Medical Distribution companies is 2.17, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ClouDr Group's current Shareholder Yield % of 20.57% is 847.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on ClouDr Group and its competitors. For the Medical Distribution industry, the median Shareholder Yield % is 2.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ClouDr Group's current Shareholder Yield % is 20.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClouDr Group stock overvalued right now?
ClouDr Group (FRA:H3L) has a current Shareholder Yield % of 20.57%. The stock's GF Value™ is €0.08, compared to a current price of €0.05 — trading 36.9% below its estimated fair value. The current Shareholder Yield % is 20.57% and 847.9% above the Medical Distribution industry median of 2.17. ClouDr Group's overall GF Score™ is 48/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For ClouDr Group (FRA:H3L), the current Shareholder Yield % is 20.57% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ClouDr Group (FRA:H3L) Overvalued in 2026?
Based on GuruFocus' analysis, ClouDr Group stock appears to be undervalued.
The current stock price of €0.05 is trading 36.9% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:H3L:
Shareholder Yield %: 20.57%
GF Value™: €0.08 vs. price of €0.05 (36.9% below fair value)
Industry Position: 847.9% above the Medical Distribution median (#14 of 114)
No single metric tells the full story. See the FRA:H3L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. The company's in-hospital solution consists of sales of medical devices, consumables, and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies, and the out-of-hospital solution connects doctors and patients, and provides high-quality and trustworthy medical services through the AI vertical model ClouD GPT. The company generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.
48GF Score
Get the complete analysis for FRA:H3L
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3L has been successfully added to your 
